Selatox Bio Pharma has entered a strategic distribution agreement covering multiple Southeast Asian markets, extending reach for its aesthetics portfolio through partners with established clinic networks and hospital channels. The agreement defines service levels for forecasting, replenishment, temperature-controlled logistics, and complaint handling with measurable KPIs reviewed quarterly.
Partners will receive training, medical affairs support, and coordinated pharmacovigilance reporting infrastructure integrated with Selatox global safety databases. Joint business plans outline education investments, congress participation, and digital tools that help practitioners access verified product information without reliance on unapproved third-party content.
Legal and compliance teams structured contracts to reinforce anti-counterfeiting measures, authorized resale restrictions, and transparent transfer pricing documentation. Both parties emphasized long-term collaboration built on quality, regulatory adherence, and clinician trust rather than short-term volume incentives alone.
Implementation workstreams are already active, covering IT connectivity for order status, localized labeling reviews, and market access sequencing based on registration status. Selatox will deploy field-based medical liaisons in select territories to support responsible adoption and feedback collection.
Executives from both organizations attended a signing ceremony in Jakarta, noting the agreement as a milestone in Indonesia-origin bio-aesthetics reaching broader ASEAN populations through disciplined commercialization.
